Altman Peter purchased $1K of BCDA

Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.

Original reporting
SEC EDGAR · Altman Peter
Published Sep 30, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The transaction is too small to affect market pricing but confirms the CEO's continued ownership.

02

Market read

Limited relevance; likely no immediate trading opportunity.

03

What to watch

Potential upcoming corporate events or financing needs that prompted the insider to increase his stake.

Relevance 4/10Novelty 3/10Timing: after market close

Background

Form 4 filing discloses a $1,030 insider purchase by BioCardia's CEO.

Company-level read

Ticker impact

$BCDANeutralLow confidence
Context

CEO Altman Peter bought 1,000 shares at $1.03 each, total $1,030, increasing his stake to 384,885 shares.

Expected impact

minimal upward pressure as a confidence signal, but size is too tiny to move the stock.

Evidence & confidence

Insider buying by a CEO can be positive, yet $1k is trivial for a listed biotech; traders are unlikely to act.

Market effects

none

none

none

Counterpoint

The purchase may be a routine portfolio adjustment rather than a strong confidence signal.

Key entities

  • Altman Peter

    President and CEO of BioCardia, Inc.

  • BioCardia, Inc.

    US-listed biotech company (ticker BCDA).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.